Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

DGMT PHCE TissUse supply order E0787301

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This contract involves the supply of tissues to support the PHCE project E0787301 operated by the Food and Drug Administration. The procurement is designated as a forecast, indicating an upcoming opportunity for vendors to provide specialized tissues, likely related to biotechnological or medical research, as suggested by the NAICS code 325414, which pertains to pharmaceutical and medicine manufacturing. Specific details such as the exact place of performance and the contracting officer are not yet determined, though the program point of contact is available through the FDA's acquisition liaison. The contract is titled "DGMT PHCE TissUse supply order E0787301" and was posted on March 11, 2026. While there is no set-aside designation indicating special participation requirements, the contract is managed by the Food and Drug Administration, reflecting its role in public health and medical research support. Interested suppliers or stakeholders can engage through the FDA contacts provided or by monitoring related procurement opportunities via the linked government industry forecast portal.

General Info

Supply of specialized tissues for FDA's PHCE project E0787301, forecasted procurement opportunity.

Agency

Food and Drug Administration → Food And Drug Administration

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing View NAICS

Place of Performance

US

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyFood and Drug Administration → Food And Drug Administration
Contacts2 people available
OfficeN/A
Organization / Agency
Food and Drug Administration → Food And Drug Administration
Office AddressN/A
Contacts
Nctr Acquisition Liaison
To Be Determined To Be DeterminedContracting Officer

Full Description

Show more
Tissues to support PHCE project E0787301

Similar Contracts

NAICS: 325414
New
Federal
iNDI FA13.1J Cell Lines Expansion and Distribution for the iPSC Neurodegenerative Disease Initiative (iNDI) ProjectThe Department of Health and Human Services, through the National Institutes of Health's National Institute on Aging, intends to award a sole source contract to The Jackson Laboratory for the expansion, quality control, biobanking, and distribution of isogenic Alzheimer’s disease and related dementias induced pluripotent stem cell lines as part of the iPSC Neurodegenerative Disease Initiative (iNDI) Project. This contract will focus on providing up to 936 specific iPSC lines, including 486 FA13.1J female SNV lines and 450 lines across 25 high-priority SNV trios, adhering to iNDI protocols for quality and expansion. The Jackson Laboratory is uniquely qualified for this contract as it currently houses the existing distribution infrastructure and has demonstrated successful past performance in supporting NIH’s iNDI requirements. The contract is planned to be a firm-fixed-price agreement with a performance period starting September 1, 2026, for a base year and up to three option years, ending August 31, 2030. The primary place of performance will be the contractor’s facility in Bar Harbor, Maine. While this notice signals the intent for a sole source award, other capable sources may submit capability statements demonstrating their ability to meet the outlined requirements, including supply of the specific cell lines, adherence to quality protocols, product and web content creation, and public distribution via an established platform. Responses must be submitted electronically by June 23, 2026, and the Government reserves the right to consider all responses but is under no obligation to initiate a competitive procurement.
National Institutes Of Health Olao

POSTED

about 18 hours ago

DEADLINE

in 12 days
View Details